NF1 and melanoma: Thus, whereas mutual exclusivity of NF1-loss, in combination with previous experimental data [26, 28, 29, 36, 38], support NF1 as a strong oncogenic driver in lung adenocarcinoma and melanoma, the general oncogenic role of RASGAP deficiency in CRC remains inconclusive.